TheraLife warning letter
This article was originally published in The Tan Sheet
Executive Summary
FDA says claims for TheraLife's Wrist, Fatigue, Neck and Back & Leg products classify them as unapproved new drugs and are misleading. The products make drug claims such as, "Treats painful and chronic conditions often experienced by computer keyboard and mouse users," according to FDA. On its Web site, the firm also says it adheres to all FDA regulatory guidelines and provides a link to FDA's 30-day structure/function claims. FDA says the company is not in compliance and is misleading by linking to FDA's site. TheraLife has 15 days to correct the violations, the agency says...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.